USP18 and hepatocellular carcinoma: In summary, our findings reveal that the inhibition of USP18 enzyme activity through HYP has the potential to sensitize and augment the effectiveness of sorafenib and regorafenib, thereby providing a promising strategy for overcoming targeted therapy resistance in HCC.